Health
China’s 2nd protein subunit COVID-19 vaccine to enter clinical trials, easy to mass produce – Global Times
China’s COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed…
Sinopharm’s COVID-19 vaccine. Photo: VCG
China’s COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed recombinant subunit vaccine candidate into clinical trials.
Sinopharm’s vaccine is the second protein subunit vaccine in the country after one developed by China’s Anhui Zhifei Longcom Biopharmaceutical Co, which started late-stage trials in Pakistan upon approval on Sunday.
The protein subunit vaccine…
-
General22 hours agoFederal government funding extends cohealth GP services until July 2026
-
Business24 hours agoWhat I’d buy if I had to invest $20,000 in ASX 200 shares before the weekend
-
General7 hours agoMildura man given 28 years to pay $73,000 in unpaid fines and tolls
-
General10 hours agoAustralia’s race to rewire the country amid a global transmission boom is not unique